On May 6, 2025, MIRA Pharmaceuticals announced that their neurotoxicity study of Ketamir-2 showed no brain toxicity, confirming it does not cause neurotoxic changes linked to ketamine. Key findings revealed no adverse effects in treated animals, which supports future regulatory submissions to the FDA.